- Oops!Something went wrong.Please try again later.
Caladrius Biosciences Inc (NASDAQ: CLBS) has received .4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.
The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.
The grant will be used to fund its upcoming Phase 3 program with simufilam, its drug candidate for Alzheimer's disease.
Price Action: CLBS shares are trading 0.68% lower at $1.45, and SAVA shares are down 2.73% at $38.16 during the market session on the last check Wednesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.